Findings from a small sample demonstrated that low TMB and PTEN mutations, particularly mutations in the domain of phosphatases may be negatively associated with the response to anti-PD-1 therapy in patients with MSI-H/dMMR gastrointestinal tumors (11). This evidence concerns the gene PTEN and digestive system neoplasm.